Nasdaq:CLDXPublished
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Study did not meet key efficacy measures or internal hurdle rate for continued development Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase Favorable safety and tolerability demonstrated, consistent…
